Day One markets Ojemda, approved for treating pediatric low-grade glioma, the most common type of brain cancer in children.

As nonprofit-governed Servier continues to make gains with its IDH-mutant glioma med Voranigo, the drugmaker is wading deeper into the rare oncology arena with a new M&A play.  | Servier on Friday ...

Relatively new to the oncology scene, Servier has built a reputation as a serial acquirer of targeted cancer outfits as it pumps up its pipeline.

PARIS, March 09, 2026 (GLOBE NEWSWIRE) -- kyron.bio, a biotechnology company pioneering precision glycoengineering for antibody therapeutic ...